arrow
M

Mark E. Burkard

university of wisconsin
H指数:38
被引数:6,921

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy of neratinib-based therapy in ERBB2-mutant lung adenocarcinomas: findings from 2 international phase 2 studies

奈拉替尼为基础疗法在ERBB2突变型肺腺癌中的疗效:2项国际II期研究的结果

2025-10-010
PRE
Stromal Versican Accumulation and Proteolysis Regulate the Infiltration of CD8+ T Cells in Breast Cancer

基质Versican积聚和蛋白酶解调控乳腺癌中CD8+ T细胞的浸润

CANCERS
IF4.4
2025-04-250
OA
Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity

亚克隆反应异质性定义癌症类器官治疗敏感性

2025-04-090
OAAI
Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy
2024-05-022
PRE
ASO Visual Abstract: Association of Neighborhood Disadvantage with Short- and Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma
2023-10-080
PRE
Neratinib plus fulvestrant plus trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
2023-10-0123
OAAI
Fragmentomic analysis of circulating tumor DNA-targeted cancer panels
2023-09-0110
PRE
CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors

CRESTONE: seribantumab在neuregulin-1 (NRG1) 融合阳性的局部晚期或转移性实体瘤成年患者中的2期研究

2023-04-145
PRE
The SMILE Study: A phase II trial of onapristone in combination with fulvestrant for patients with ER-positive and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 inhibitors
2023-03-010
PRE
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
2023-02-0715
OA